LeMaitre Vascular, Inc. $LMAT Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 304,556 shares of the medical instruments supplier’s stock after purchasing an additional 19,447 shares during the quarter. Envestnet Asset Management Inc. owned about 1.35% of LeMaitre Vascular worth $25,293,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. grew its holdings in shares of LeMaitre Vascular by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock worth $9,385,000 after purchasing an additional 3,248 shares during the period. US Bancorp DE grew its holdings in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 368 shares during the period. Northern Trust Corp grew its holdings in shares of LeMaitre Vascular by 5.4% during the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock worth $28,993,000 after purchasing an additional 17,748 shares during the period. Congress Asset Management Co. grew its stake in shares of LeMaitre Vascular by 4.6% in the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after buying an additional 29,553 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at about $892,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Barrington Research restated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Cantor Fitzgerald upped their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $98.75.

LeMaitre Vascular Trading Up 0.4%

NASDAQ LMAT opened at $86.92 on Tuesday. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 42.19, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company’s fifty day moving average price is $90.29 and its two-hundred day moving average price is $87.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same quarter in the prior year, the business posted $0.52 EPS. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

Insider Transactions at LeMaitre Vascular

In other news, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at approximately $269,875.80. This trade represents a 69.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David B. Roberts sold 10,815 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the sale, the director directly owned 17,976 shares in the company, valued at approximately $1,660,802.64. This represents a 37.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 120,815 shares of company stock valued at $11,280,206 in the last three months. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.